Corbus Pharmaceuticals Holdings (CRBP) Non Operating Income (2013 - 2025)

Corbus Pharmaceuticals Holdings' Non Operating Income history runs 13 years deep, the most recent figure standing at $1.1 million for Q3 2025.

• On a quarterly basis, Non Operating Income fell 37.57% year-over-year to $1.1 million in Q3 2025; TTM through Sep 2025 was $8.4 million, a 12.21% increase from a year earlier, with the FY2024 full-year figure at $8.5 million, up 1695.78% from the prior year.
• Non Operating Income slipped to $1.1 million in Q3 2025 per CRBP's latest filing, from $1.5 million in the prior quarter.
• Across five years, Non Operating Income topped out at $21.0 million in Q4 2021 and bottomed at -$920083.0 in Q1 2022.
• The 5-year median for Non Operating Income is $991000.0 (2024), against an average of $2.3 million.
• Across the five-year window, Non Operating Income sank 1410.51% in 2021 and surged 2631.83% in 2023, its largest moves.
• Year by year, Non Operating Income stood at $21.0 million in 2021, then tumbled by 100.39% to -$82233.0 in 2022, then jumped by 2631.83% to $2.1 million in 2023, then soared by 47.69% to $3.1 million in 2024, then tumbled by 65.04% to $1.1 million in 2025.
• Per Business Quant, the three latest CRBP Non Operating Income figures stand at $1.1 million (Q3 2025), $1.5 million (Q2 2025), and $2.8 million (Q1 2025).